Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α – benralizumab

Hypereosinophilic syndrome (HES) is a group of a rare diseases characterized by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a humanized, monoclonal antibody against interleukin 5 (IL-5) receptor α, which is expressed on human eosinophils. He...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosałka-Węgiel, Joanna, Milewski, Mamert, Siwiec, Andżelika, Strach, Magdalena, Ochrem, Bogdan, Korkosz, Mariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574116/
https://www.ncbi.nlm.nih.gov/pubmed/34764813
http://dx.doi.org/10.5114/ceji.2021.108259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574116/
https://www.ncbi.nlm.nih.gov/pubmed/34764813
http://dx.doi.org/10.5114/ceji.2021.108259

Ejemplares similares